This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.
A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Positive final results from Phase 2 trial of VB10.16 in advanced cervical cancer
Expansion of the clinical collaboration with Roche combining VB10.16 with atezolizumab in the potentially registrational trial, C-04, in advanced cervical cancer
Well-capitalizedwith a cash position of $174m at June 30, 2023
Post period update:
Approval from competent authorities in all eight European countries for the VB-C-03 trial with VB10.16 in combination with KEYTRUDA®1 (pembrolizumab) in PD-L1 positive 1st line head and neck cancer
Safety clearance of the 9 mg dose of VB10.NEO in the VB-N-02 trial, with no safety concerns and no dose-limiting toxicities observed
Henrik Søndergaard hired to lead the dedicated Autoimmune research group
1: KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Rich and diversified pipeline
Upcoming
Asset
Indication
Rights
Preclinical
Phase 1
Phase 2
Phase 3
Catalyst
Oncology
HPV16+ cervical cancer
1
VB10.16
Off-the-shelf
HPV16+ head and neck cancer
2
Regeneron
Undisclosed
3
programs
Undisclosed
Internal
Melanoma, lung, bladder, renal,
4
head and neck cancer; locally
Individua-
advanced and metastatic
lized
VB10.NEO
tumors
Locally advanced and
4
metastatic tumors
Infectious Disease
3
Regeneron programs
Undisclosed
Internal
Undisclosed
Autoimmune
Initiate trial (Q4 2023)
FPFD
(Q3 2023)
Update (Q4 2023)
Internal
Undisclosed
Update (Q3 2023)
1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO.
Nykode Therapeutics AS published this content on 23 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 August 2023 18:48:07 UTC.
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeuticsâ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
NYKODE THERAPEUTICS 
